{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:14:37Z","timestamp":1787786077709,"version":"build-2784847793"},"reference-count":88,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"David Wohlscheid Fund"},{"DOI":"10.13039\/100001181","name":"Inova Health System Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,1,2]]},"DOI":"10.1080\/14737140.2025.2575827","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:31:49Z","timestamp":1760531509000},"page":"93-104","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Harnessing genomic profiling for improved urothelial cancer outcomes"],"prefix":"10.1080","volume":"26","author":[{"given":"Eun-Mi","family":"Yu","sequence":"first","affiliation":[{"name":"Inova Schar Cancer Institute","place":["Fairfax, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Linville","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute","place":["Fairfax, USA"]},{"name":"Johns Hopkins School of Medicine","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Woo","family":"Hwang","sequence":"additional","affiliation":[{"name":"Jefferson Memorial Health System","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Catholic Medical University St. Mary\u2019s Hospital","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Li","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute","place":["Fairfax, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanny B.","family":"Aragon-Ching","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute","place":["Fairfax, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"GLOBOCAN 2022: Bladder cancer 9th most common worldwide [Internet]. World Bladder Cancer Patient Coalition. [cited 2025 May 5]. Available from: https:\/\/worldbladdercancer.org\/news_events\/globocan-2022-bladder-cancer-is-the-9th-most-commonly-diagnosed-worldwide\/"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061115"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1928-x"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.013"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.02.010"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000538237"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.11"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60040585"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.12.007"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00143"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.009"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.034"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.039"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.08.001"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.01.006"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.008"},{"key":"e_1_3_5_23_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer V.1. \u00a9 National Comprehensive Cancer Network Inc. 2025. All rights reserved. 2025 [cited 2025 Jun 29]. To view the most recent and complete version of the guideline go online to NCCN.org."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.12.009"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002261"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.03.030"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071784"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.10.035"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18640-0"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00274"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02303"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.10.004"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.629"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.794"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00221"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.662"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS904"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0087"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6795"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2411"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.409"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30541-6"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01579-0"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0314-1"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231192402"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0244"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56462-0"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29441-y"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000335"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002317"},{"key":"e_1_3_5_58_1","unstructured":"Gilead Provides Update on U.S. Indication for Trodelvy\u00ae in metastatic urothelial cancer [internet]. [cited 2025 Jul 19]. Available from: https:\/\/www.gilead.com\/company\/company-statements\/2024\/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yao.2023.01.010"},{"key":"e_1_3_5_61_1","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with Nectin-4\u2013positive solid tumors, including metastatic urothelial carcinoma","author":"Rosenberg J","unstructured":"Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with Nectin-4\u2013positive solid tumors, including metastatic urothelial carcinoma. Journal of Clinical Oncology [internet]. [cited 2025 May 5]. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.02044","journal-title":"Journal of Clinical Oncology [internet]"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01643"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4175"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.15130"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000938"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16643"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1764"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33658"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03489"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.11.005"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29060312"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.011"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.796"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.603"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1011885"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102351"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2488"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2023.02.003"},{"issue":"1","key":"e_1_3_5_80_1","first-page":"326","article-title":"Clinical features of patients with MTAP-deleted bladder cancer","volume":"13","author":"De Souza AL","year":"2023","unstructured":"De Souza AL, Mega AE, Douglass J, et al. Clinical features of patients with MTAP-deleted bladder cancer. Am J Cancer Res. 2023;13(1):326\u2013339.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-024-00529-y"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26421-6"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1701"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1215"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147819"},{"key":"e_1_3_5_86_1","unstructured":"FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. FDA [Internet]. 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2025.2517581"},{"key":"e_1_3_5_88_1","unstructured":"Sonpavde GP. Imvigor011 bladder cancer trial achieves positive results with SignateraTM strongly predicting adjuvant immunotherapy benefit [internet]. Natera. [cited 2025 Aug 30]. Available from: https:\/\/www.natera.com\/company\/news\/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit\/"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-68505-7_13"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.04.013"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2575827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:57:32Z","timestamp":1767592652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2575827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"alternative-id":["10.1080\/14737140.2025.2575827"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2575827","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}